Oral, once-weekly XPOVIO dosing

hero bg detail - dots

Before starting therapy and during treatment with XPOVIO + Vd, provide 2 antiemetics1,2

Graphic shows 2 antiemetics Graphic shows 2 antiemetics

NK-1 antagonists (eg, aprepritant or rolapitant7,8) can be used in place of a D2/5-HT2A antagonist.2,5

Antiemetics such as NK-1 inhibitors and olanzapine can be reduced or stopped after 8 weeks if patients are tolerating selinexor.2

For reference purposes only. All treatment decisions must be individualized and made solely at the discretion of the healthcare professional.

Considerations when starting a patient on XPOVIO + Vd1,2,9-11

Graphic shows considerations with starting a patient on XPOVIO +Vd Graphic shows considerations with starting a patient on XPOVIO +Vd

Recommended monitoring and management for adverse reactions1

Fluid intake

Ensure patients maintain adequate fluid and caloric intake throughout treatment

IV hydration

Consider IV hydration and replace electrolytes as clinically indicated

Monitor CBC

Monitor CBC with differential, standard blood chemistries, body weight, nutritional status, and volume status at baseline and during treatment as clinically indicated

Thrombocytopenia

Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia

Obtain white blood cell counts with differential at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of concomitant infection and evaluate promptly. Consider supportive measures, including antimicrobials and growth factors (eg, G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Hyponatremia

Monitor sodium level at baseline and throughout treatment. Monitor more frequently during the first 2 months of treatment. Correct sodium levels for concurrent hyperglycemia (serum glucose >150 mg/dL) and high serum paraprotein levels. Assess hydration status and manage hyponatremia per clinical guidelines, including intravenous saline and/or salt tablets as appropriate and dietary review. Interrupt, reduce dose, or permanently discontinue based on severity of the adverse reaction.

icon background img Important information

Please see the recommended dosage modification guidelines and additional considerations in the full Prescribing Information.

Additional dosing information1

  • Each XPOVIO dose should be taken at approximately the same time of day
  • Each tablet should be swallowed whole with water
  • Do not break, chew, crush, or divide the tablets
  • If a dose of XPOVIO is missed or delayed, instruct patients to take their next dose at the next regularly scheduled time
  • If a patient vomits a dose of XPOVIO, the patient should not repeat the dose and should take the next dose on the next regularly scheduled day

In the XVd trial, nausea was transient and reversible12

With 92% of the cases resolved/resolving in the first month

Graph shows the percentage of patients experiencing nausea events in the XVd arm of the XVd trial in multiple myeloma Graph shows the percentage of patients experiencing nausea events in the XVd arm of the XVd trial in multiple myeloma
icon background img Important information

Before starting therapy and during treatment with XPOVIO, provide 2 prophylactic antiemetics1,2

  • For grades 1 and 2 nausea: Maintain XPOVIO dose and add additional antiemetics
  • For grade 3 nausea: Interrupt XPOVIO, monitor nausea, add additional antiemetics, and restart XPOVIO at 1 dose level lower

One or both antiemetics may be tapered after 8 weeks of therapy.

For additional information, please see Section 2, “Dosage and Administration,” of the XPOVIO US Prescribing Information.

Next steps

Abbreviations: CBC, complete blood count; G-CSF, granulocyte colony-stimulating factor; IV, intravenous; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.

References: 1. XPOVIO (selinexor) [prescribing information]. Newton, MA. Karyopharm Therapeutics, Inc. 2. Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020;34(9):2430-2440. doi:10.1038/s41375-020-0756-6 3. Zofran. Prescribing information. GlaxoSmithKline; 2016. 4. Chari A, Florendo E, Mancia IS, et al. Optimal supportive care with selinexor improves outcomes in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(12):e975-e984. doi:10.1016/j.clml.2021.07.014 5. Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11(5):89. doi:10.1038/s41408-021-00478-4 6. Saudemont G, Prod’Homme C, Da Silva A, et al. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care. 2020;19:56. doi:10.1186/s12904-020-00559-4 7. Emend. Prescribing information. Merck & Co., Inc; 2022. 8. Varubi. Prescribing information. TerSera Therapeutics LLC; 2017. 9. Data on file. Karyopharm Therapeutics Inc. 2021. 10. Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer. 2015;23(5):1431-1445. doi:10.1007/s00520-014-2552-1 11. Kurtin S. Living with multiple myeloma: a continuum-based approach to cancer survivorship. Semin Oncol Nurs. 2017;33(3):348-361. doi:10.1016/j.soncn.2017.05.009 12. Data on file [1]. Karyopharm Therapeutics Inc. 2021. 13. Data on file [2]. Karyopharm Therapeutics Inc. 2021.

+

INDICATION

XPOVIO® (selinexor) is a prescription medicine approved in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.


IMPORTANT SAFETY INFORMATION

Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma.

Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of bleeding. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection.

Monitor more frequently during the first 3 months of treatment. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity: XPOVIO can cause severe gastrointestinal toxicities in patients.

Nausea/Vomiting/Diarrhea: Provide prophylactic antiemetics or treatment as needed.

Anorexia/Weight Loss: Monitor weight, nutritional status, and volume status at baseline and throughout treatment and provide nutritional support, fluids, and electrolyte repletion as clinically indicated.

Hyponatremia: XPOVIO can cause severe or life-threatening hyponatremia.

Monitor sodium level at baseline and throughout treatment.

Serious Infection: XPOVIO can cause serious and fatal infections. Atypical infections reported after taking XPOVIO include, but are not limited to, fungal pneumonia and herpesvirus infection.

Neurological Toxicity: XPOVIO can cause life-threatening neurological toxicities.

Coadministration of XPOVIO with other products that cause dizziness or mental status changes may increase the risk of neurological toxicity.

Advise patients to refrain from driving and engaging in hazardous occupations or activities, until the neurological toxicity fully resolves. Institute fall precautions as appropriate.

Embryo-Fetal Toxicity: XPOVIO can cause fetal harm when administered to a pregnant woman.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

Cataracts: New onset or exacerbation of cataract has occurred during treatment with XPOVIO. The incidence of new onset or worsening cataract requiring clinical intervention was reported.

ADVERSE REACTIONS

The most common adverse reactions (ARs) (≥20%) in patients with multiple myeloma who received XVd were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.

Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.

Fatal ARs occurred in 6% of patients within 30 days of last treatment. Serious ARs occurred in 52% of patients. Treatment discontinuation rate due to ARs was 19%. The most frequent ARs requiring permanent discontinuation in >2% of patients included fatigue, nausea, thrombocytopenia, decreased appetite, peripheral neuropathy and vomiting. Adverse reactions led to XPOVIO dose interruption in 83% of patients and dose reduction in 64% of patients.

USE IN SPECIFIC POPULATIONS

No overall difference in effectiveness of XPOVIO was observed in patients >65 years old when compared with younger patients. Patients ≥65 years old had a higher incidence of discontinuation due to an adverse reaction (AR) and a higher incidence of serious ARs than younger patients.

The effect of end-stage renal disease (CLCR <15 mL/min) or hemodialysis on XPOVIO pharmacokinetics is unknown.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1-888-209-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

© 2023 Karyopharm Therapeutics Inc.

X